<DOC>
	<DOCNO>NCT00002482</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I/II trial study effectiveness monoclonal antibody cyclophosphamide treat patient metastatic cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Plus Cyclophosphamide Treating Patients With Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate clinical feasibility toxicity monoclonal antibody OKT3 give low-dose cyclophosphamide patient advanced malignancy . II . Perform serial immune monitoring patient treated regimen . III . Identify clinical response produce regimen . OUTLINE : Biological Response Modifier Therapy Suppressor Cell Inhibition . Anti-CD3 Murine Monoclonal Antibody OKT3 , MOAB OKT3 ; Cyclophosphamide , CTX , NSC-26271 . PROJECTED ACCRUAL : At least 9 evaluable patient per diagnostic category require initially ; response see dose-finding portion study , total 24 patient diagnosis enter .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Muromonab-CD3</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Metastatic cancer consider incurable standard therapy high priority protocol available Locally progressive primary brain tumor ( e.g. , astrocytoma , glioma ) also eligible Brain metastasis allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 04 ( poor performance status brain tumor patient specifically eligible ) Life expectancy : At least 2 month Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Pulmonary : No history adult asthma No emphysema No pulmonary insufficiency No pulmonary edema Other : No AIDS positive HIV serology No pregnant woman PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>